Marcus F K P Ramos1, Marina A Pereira2, Larissa C Amorim3, Evandro S de Mello2, Sheila F Faraj2, Ulysses Ribeiro1, Paulo M G Hoff3, Ivan Cecconello1, Tiago B de Castria3,4. 1. Department of Gastroenterology, Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil. 2. Department of Pathology, Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil. 3. Department of Radiology and Oncology, Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil. 4. Sirio-Libanes Hospital, Sao Paulo, Brazil.
Abstract
BACKGROUND: Gastric cancer (GC) has been defined in distinct molecular subtypes with different therapeutic implications. However, its clinical significance and prognosis regarding standard chemotherapy (CMT) remains unclear. This study aimed to analyze the impact of perioperative or adjuvant treatment among subtypes of GC. METHODS: We retrospectively evaluated all stage II/III patients with GC who underwent a curative gastrectomy. Based on immunohistochemistry and in situ hybridization techniques, GC was classified into five subtypes: Epstein-Barr virus (EBV) positive, microsatellite instability (MSI), e-cadherin aberrant, p53-aberrant, and p53-normal. RESULTS: Among the 178 CG included, 111 patients received CMT and 67 were treated with surgery alone. Survival analysis showed that p53-aberrant GC treated with CMT had better disease-free survival (DFS) compared with surgery alone (P = .001).There was no significant difference in DFS between patients who received CMT and those with surgery alone for EBV, MSI, E-cadherin, and p53-normal GC. An improvement in overall survival was observed only for E-cadherin (P = .001) and p53-aberrant (P < .001) patients who received CMT. CONCLUSIONS: CMT showed different impact on the survival of CG according to the molecular subtype. No survival benefit was observed for EBV and MSI groups who received CMT. GC with p53-aberrant had a significant benefit in survival with standard therapy.
BACKGROUND:Gastric cancer (GC) has been defined in distinct molecular subtypes with different therapeutic implications. However, its clinical significance and prognosis regarding standard chemotherapy (CMT) remains unclear. This study aimed to analyze the impact of perioperative or adjuvant treatment among subtypes of GC. METHODS: We retrospectively evaluated all stage II/III patients with GC who underwent a curative gastrectomy. Based on immunohistochemistry and in situ hybridization techniques, GC was classified into five subtypes: Epstein-Barr virus (EBV) positive, microsatellite instability (MSI), e-cadherin aberrant, p53-aberrant, and p53-normal. RESULTS: Among the 178 CG included, 111 patients received CMT and 67 were treated with surgery alone. Survival analysis showed that p53-aberrant GC treated with CMT had better disease-free survival (DFS) compared with surgery alone (P = .001).There was no significant difference in DFS between patients who received CMT and those with surgery alone for EBV, MSI, E-cadherin, and p53-normal GC. An improvement in overall survival was observed only for E-cadherin (P = .001) and p53-aberrant (P < .001) patients who received CMT. CONCLUSIONS:CMT showed different impact on the survival of CG according to the molecular subtype. No survival benefit was observed for EBV and MSI groups who received CMT. GC with p53-aberrant had a significant benefit in survival with standard therapy.
Authors: Run Cong Nie; Guo Ming Chen; Shu Qiang Yuan; Jin Won Kim; Jie Zhou; Man Nie; Zhi Wei Zhou; Yun Wang; Yuan Fang Li; Chen Yang Feng; Ying Bo Chen; Shi Chen Journal: Ann Surg Oncol Date: 2021-11-18 Impact factor: 5.344
Authors: Ana Bermúdez; Isabel Arranz-Salas; Silvia Mercado; Juan A López-Villodres; Virginia González; Francisca Ríus; María V Ortega; Carmen Alba; Isabel Hierro; Diego Bermúdez Journal: Diagnostics (Basel) Date: 2021-05-25
Authors: Alice Cristina Castro DA Silva; Marina Alessandra Pereira; Marcus Fernando Kodama Pertille Ramos; Leonardo Cardili; Ulysses Ribeiro; Bruno Zilberstein; Evandro Sobroza de Mello; Tiago Biachi de Castria Journal: Arq Bras Cir Dig Date: 2022-01-31
Authors: Jean Paul Nshizirungu; Sanae Bennis; Ihsane Mellouki; Mohammed Sekal; Dafr-Allah Benajah; Nada Lahmidani; Hicham El Bouhaddouti; Karim Ibn Majdoub; Sidi Adil Ibrahimi; Sónia Pires Celeiro; Marta Viana-Pereira; Fernanda Franco Munari; Guilherme Gomes Ribeiro; Vinicius Duval; Iara Santana; Rui Manuel Reis Journal: Dis Markers Date: 2021-07-28 Impact factor: 3.434